ReleaseWire Connect

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market:INNV), an emerging commercial stage cash flow positive pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories received the approval of the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® from the Indian FDA, The Drugs Controller General (India), and the Directorate General of Health Services to commercialize the products in India.

Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV) announced today it will release its second quarter 2016 financial results before the open of trading on Tuesday August 9, 2016 ahead of its 10-Q to be filed on August 15, 2016. The company will host a conference call at 4:15 p.m. EDT/1:15 p.m. PDT on the same day (August 9, 2016) to discuss the financial results and recent business developments.

Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV) announced today it has re-appointed PT Laras Bumi Resources ("LB Resources") as its agent for the distribution of its product Zestra® to increase Female Sexual Arousal and Desire and Satisfaction in select Asian countries. Based in Indonesia ("LB Resources") has extensive distribution in Japan, China, Indonesia and South Korea. LB Resources projects an initial ordering annual volume close to 150,000 units a year.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB:INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today, the closing of its previously announced $3 million private financing from institutional investors.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB:INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today, the closing of $1.5 million convertible promissory note investment from institutional investors. The convertible promissory notes have a $0.25 fixed conversion price and bear an interest rate of 10% and mature in 13 months.

SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at the underserved Female Sexual Interest Arousal Dysfunction (FSI/AD) market and Innovus Pharmaceuticals' (OTCQB:INNV) clinically proven over-the-counter treatment, Zestra®.

The global erectile dysfunction drug market is expected to reach $3.2 billion by 2022, according to Grand View Research Inc., with drugs like Viagra and Cialis leading the way. Through the use of nitric oxide conversion, these phosphodiesterase type 5 inhibitors (PDE5) based drugs increase blood flow to the penis and enable a natural erection to take place. The problem is that these drugs tend to lose efficacy over time with 40% of men stopping use of the drug.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB:INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today that the Company has reduced its debt obligation by $1.5 million and also eliminated approximately $300k in derivative liabilities as of 3/31/16, resulting in a total reduction of outstanding liabilities of over $1.8 million.

The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCMKTS:INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories filed the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® with the Indian FDA, The Drugs Controller General (India) and the Directorate General of Health Services to commercialize the products in India.